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Peripheral T-cell lymphomas (PTCL) are a diverse group of lymphoproliferative disorders,
which share a common denominator of overall poor prognosis, with few exceptions. In
this article, the authors review current standard of care approaches for the treatment of
PTCLs, the role of stem-cell/bone marrow transplantation, and current developments in
novel targeted therapies.
Keywords: PTCL, ALCL, brentuximab, pralatrexate, romidepsin, alisertib, zanolimumab, bortezomib
DEFINITION AND INTRODUCTION
Peripheral T-Cell lymphomas (PTCL) are a diverse group of
lymphoproliferative disorders with different biological and clin-
ical behavior. Comparatively to their B-cell counterparts, PTCLs
are significantly rarer and more difficult to treat, either due to
the paucity of large trials carrying the evidence to suggest spe-
cific therapeutic approaches, or due to the biology of the dis-
ease. When compared to B-cell NHL, the prognosis for PTCL
remains poor, mainly due to lower response rates and shorter
duration of response to standard combination chemotherapy
regimens.
Peripheral T-Cell lymphomas account for 10–15% of all NHLs
in North America, and are characterized by the presence of malig-
nant mature T-cells (derived from post-thymic T-cells) or NK cells
(Savage, 2007). Some forms of PTCL are more common, or have
distinct molecular and clinical features that may dictate therapeu-
tic choices, but, overall, PTCL has classically been treated with
regimens adapted from B-cell lymphomas, with generally poor
outcomes.
In 2008, the fourth edition of the World Health Organiza-
tion (WHO) Classification of Tumors of Hematopoietic and Lym-
phoid Tissues (Swerdlow, 2008) was published, and subdivided
PTCL even further. While this was helpful in providing clini-
cians with more accurate information to predict prognosis, it
has not translated, so far, into a guide for better therapeutic
choices. The International T-cell and natural killer/T-cell lym-
phoma study (Vose et al., 2008) provided insight into the epi-
demiology of this group of diseases. Based on their results, the
most common subtype of mature T-cell lymphomas is PTCL,
non-otherwise specified (PTCL, NOS; 26%), followed by angioim-
munoblastic T-cell lymphoma (AITL; 18.5%), anaplastic large cell
lymphoma,ALK-positive (ALCL,ALK+; 7%), and anaplastic large
cell lymphoma, ALK-negative (ALCL, ALK−; 6%). Interestingly,
PTCLs show significant variation in geographic and racial distri-
bution. In Asian populations, for instance, PTCLs are responsible
for a larger proportion of NHL, which could be a result both from
a true increased incidence, as well as a relative decrease of some
subtypes of B-cell lymphomas which are more commonly seen in
North American and European populations (i.e., follicular lym-
phoma). Another explanation would be the increased incidence
of adult T-cell leukemia/lymphoma (ATL) in regions where the
human T-cell lymphotropic virus 1 (HTLV-1) is endemic, such as
Japan and the Caribbean.
Peripheral T-Cell lymphomas-NOS is the most common sub-
type of T-cell lymphoma, usually involving nodal sites, with many
patients presenting with extra-nodal involvement of the gastroin-
testinal system, liver, bone marrow, and spleen. When compared
to B-cell NHLs, PTCL-NOS present a poorer overall survival (OS)
and progression-free survival (PFS) (Savage et al., 2004). AITL
usually presents in older patients, with diffuse lymphadenopathy,
many times associated to hepatosplenomegaly, eosinophilia, skin
rash, fever, and hypergammaglobulinemia. Prognosis is similar to
PTCL-NOS, with 5-year OS rate of 33% (Mourad et al., 2008).
ALCL, ALK+ is a CD30-expressing type of PTCL, characterized
by the over expression of ALK-1 protein, which results from the
chromosomal translocation t (2;5) (Mourad et al., 2008; Swerd-
low, 2008). It usually presents in children on younger patients,
and carries an overall good prognosis, when compared to its ALK-
negative counterpart, which usually presents in older patients.
Five-year OS rates following anthracycline-based chemotherapy
have been reported as 79% for ALCL, ALK+ and 46% for ALCL,
ALK− (Gascoyne et al., 1999).
In this review, we will discuss standard therapeutic approaches
for PTCLs, as well as novel therapeutic agents.
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FRONTLINE THERAPY
There is no consensus among specialists regarding standard
frontline therapy for PTCL.
Commonly, CHOP (cyclophosphamide, doxorubicin, vin-
cristine, prednisone) is the “go-to” chemotherapy regimen of
choice for PTCL (Broussais-Guillaumot et al., 2013), despite evi-
dence that, except for ALCL, ALK+, it is largely ineffective, as
evidenced by a large retrospective analysis from the German High-
Grade Non-Hodgkin Lymphoma Study Group (Schmitz et al.,
2010). In this analysis, 343 patients with a diagnosis of PTCL
were treated with six to eight cycles of CHOP or CHOP plus
etoposide (CHOEP). Three-year event-free survival (EFS) and OS
for patients in the four major subtypes were 75.8 and 89.8% for
ALK-positive ALCL; 50.0 and 67.5% for AITL; 45.7 and 62.1% for
ALK-negative ALCL; 41.1 and 53.9% for PTCL-NOS. In younger
patients with normal lactate dehydrogenase (LDH), the addition of
etoposide to CHOP significantly improved 3-year EFS (75.4 versus
51.0%, P < 0.003), but there was no statistically significant differ-
ence in OS. For patients older than 60 years of age, the addition of
etoposide did not yield any advantage, mainly due to added toxi-
cities. This analysis also took into consideration patients in trials
of dose intensification or dose escalation of CHOP/CHOEP, and
found no improvement in OS when compared to standard CHOP
given every 21 days.
More intensive chemotherapy regimens, such as hyperfraction-
ated cyclophosphamide, vincristine, doxorubicin, and prednisone
(hyper-CVAD) were compared to CHOP in a retrospective analy-
sis by the MD Anderson group (Escalon et al., 2005), and showed
no additional benefit. Clinical outcomes for 135 patients with
previously untreated PTCL, who received frontline therapy, were
evaluated. The estimated 3-year OS for patients receiving CHOP
was 62%, while for patients receiving intensive therapy it was 56%.
When patients with a diagnosis of ALCL were excluded from the
analysis, the 3-year OS was 43% for patients treated with CHOP
and 49% for patients treated with intensive therapy. Additionally,
the investigators identified parameters that may be independent
prognostic factors in PTCL (excluding ALCL), such as ECOG per-
formance status >2, beta-2-microglobulin level >2 mg/L, LDH
level higher than normal, bulky disease ≥7 cm, and a higher
international prognostic index (IPI).
Bortezomib, a selective inhibitor of the proteasome 26S,
involved in the NF-κB cell signaling pathway, has been evaluated
for treatment of patients with PTCL. A Phase I study of bortezomib
used in association with CHOP chemotherapy was conducted in
13 patients with advanced PTCL or NK/T-cell lymphoma (Lee
et al., 2008). The reported CR rate was 62%, with no data pub-
lished on PFS or OS. A phase II study of bortezomib as a single
agent for patients with relapsed PTCL (n= 2) or cutaneous T-
cell lymphoma (CTCL) (n= 13) reported objective response rates
(ORR) of 67%, with a duration of response ranging from 7 to
14 months and both patients with PTCL achieving CR (Zinzani
et al., 2007).
Recently, results of a Phase II trial combining bortezomib to
CHOP chemotherapy in the frontline setting for patients with
stage III/IV PTCL were published (Kim et al., 2012). Of the
46 patients enrolled, 30 achieved a CR (65%), with an ORR of
76%. In spite of good initial response rates, the 3-year OS and
PFS rates were 47 and 35% respectively, not much different than
historical controls using CHOP alone as frontline therapy. Borte-
zomib remains an attractive agent for prospective clinical trials
in patients with PTCL. Given the low rates of significant compli-
cations, association of bortezomib with standard chemotherapy
should be further studied.
Gallamini et al. (2007) have reported a prospective Phase II trial
of frontline CHOP combined to the anti-CD52 monoclonal anti-
body alemtuzumab (CHOP-C), for 24 patients with a diagnosis
of PTCL. Complete remission was achieved in 71% of patients
and after a median follow-up of 16 months, median duration
of response was 11 months. Two Phase III trials in Europe are
currently recruiting patients with PTCL for a prospective compar-
ison between CHOP and CHOP-C as frontline therapy (ACT-1
and ACT-2 trials). Other efforts are underway, attempting to
improve response and survival rates combining other novel agents
to CHOP.
THE ROLE OF AUTOLOGOUS STEM-CELL TRANSPLANT
Given the overall poor outcomes with conventional therapy as
frontline treatment for PTCL, the role of high-dose chemotherapy
with autologous stem-cell rescue (HDT/ASCR) has been studied
as a consolidation option after successful frontline therapy. Several
retrospective studies have reported favorable outcomes for consol-
idation HDT/ASCR, with 3-year OS and PFS ranging from 53 to
58% and 44 to 50%, respectively (Schetelig et al., 2003; Jantunen
et al., 2004; Feyler et al., 2007; Kim et al., 2007a; Rodriguez et al.,
2007a; Kyriakou et al., 2008; Yang et al., 2009). Prospective stud-
ies solidified the role of HDT/ASCR in PTCL by yielding positive
outcomes in this patient population. Table 1 depicts some of these
studies.
To date, there are no published randomized trials comparing
conventional chemotherapy alone to first-line consolidation with
HDT/ASCR, so the true impact of this treatment modality on
survival rates has not been completely established. In light of the
available data, HDT/ASCR remains a reasonable treatment modal-
ity for patients with a good performance status who present a
significant response to frontline therapy.
THE ROLE OF ALLOGENEIC HEMATOPOIETIC BONE MARROW
TRANSPLANT
Given the significant relapse rates after frontline therapy for
PTCL, even after consolidation with HDT/ASCR in first remis-
sion, there has been increasing interest in allogeneic hematopoietic
bone marrow transplant (allo-BMT) as a treatment modality,
due to its potential in eliciting a graft-versus-lymphoma (GVL)
effect. Recently, the Johns Hopkins group reported on 44 con-
secutive patients who underwent related-donor allo-BMTs for
PTCL, including 22 haploidentical grafts (Kanakry et al., 2013).
Most patients presented with poor-risk disease, with 60% hav-
ing received at least two prior chemotherapy regimens, 50% had
history of chemorefractory disease and 25% had active disease at
the time of allogeneic stem-cell transplantation (allo-SCT). Grafts
were marrow derived in 43 of the cases. Patients received either
a reduced intensity conditioning (RIC) regimen (n= 24) or a
myeloablative conditioning (MAC) regimen (n= 20). Estimated
2-year PFS for all patients was 40% and OS was 43%. There was
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Table 1 | Clinical trials of HDT/ASCR for PTCL.
Reference Regimen Number of patients OS rate PFS rate
GEL-TAMO (Rodriguez
et al., 2007b)
MegaCHOP ×3, followed by HDT/ASCR (in
unresponsive patients, addition of
ifosfamide+etoposide ×2 prior to HDT/ASCR)
26 (ALCL,
ALK+excluded)
73% at 3 years 53% at 3 years
NLG-T-01 (d’Amore
et al., 2012)
CHOEP-14 ×6, followed by HDT/ASCR (in patients
>60 years of age, etoposide was excluded)
166 (ALCL,
ALK+excluded)
51% at 5 years 44% at 5 years
Corradini et al. (2006) APO ×2+DHAP ×2, followed by HDT/ASCR or
MACOP-B 8 weeks followed by HDT/ASCR
62 34% at 12 years 30% at 12 years
GELCAB (Mercadal
et al., 2008)
High-dose CHOP/ESHAP ×6 followed by HDT/ASCR 41 (ALCL,
ALK+excluded)
39% at 4 years 30% at 4 years
Reimer et al. (2009) CHOP ×4–6, followed by HDT/ASCR 83 48% at 3 year (for
patients in CR)
36% at 3 year
CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; APO, doxorubicin, vincristine, prednisone; DHAP, dexamethasone, cytarabine, cis-
platin; MACOP-B, methotrexate, cytarabine, cyclophosphamide, vincristine, prednisone, and bleomycin; ESHAP, etoposide, methylprednisolone, cytarabine, and
cisplatin; HDT/ASCR, high-dose chemotherapy/autologous stem-cell rescue; ALCL, anaplastic large cell lymphoma.
a non-statistically significant trend toward better PFS for patients
receiving allo-BMT in first remission, versus beyond first remis-
sion (53% at 2 years, versus 29%, p= 0.08). The 1-year estimated
non-relapse mortality (NRM) was 10% for patients receiving MAC
and 8% for patients receiving RIC (11% for RIC/haploidentical
transplants).
This PTCL-restricted series show that using RIC regimens for
patients with high-risk PTCL is feasible, with less NRM when
compared to the use of MAC regimens. A remarkable tendency
toward better PFS when performing allo-BMT following first
remission may help solidify the role of this therapeutic approach
for PTCL, although further comparative studies are needed to
better elucidate the appropriate timing for allo-BMT. With contin-
uous efforts toward augmentation of GVL effect while minimizing
graft-versus-host disease (GVHD) and transplant-related toxic-
ities, especially when using RIC regimens, allo-BMT may play
an important role in the management of PTCLs in the near
future.
TREATMENT FOR RELAPSED/REFRACTORY DISEASE
Until recently, salvage therapy modalities for relapsed/refractory
PTCL were restricted to combination chemotherapy regimens
derived from B-cell lymphoma trials, followed by HDT/ASCR or
allo-SCT. Second-line chemotherapy with ICE (ifosfamide, cis-
platin, etoposide) followed by HDT/ASCR, for example, yielded
a median PFS of only 6 months (counted from the last treatment
with ICE), with 70% of patients relapsing at 1 year (Horwitz et al.,
2005).
For allo-SCT, a retrospective analysis conducted in France
revealed 5-year EFS and OS of 53 and 57%, respectively, but with
a 5-year transplant-related mortality (TRM) of 34% and an early
TRM (<100 days) rate of 21% (Le Gouill et al., 2008). Additional
retrospective analyses are available, but none revealed 3-year OS
rates higher than 40–45%, with a repeatedly significant early TRM
rate across analyses (Smith et al., 2010; Beitinjaneh et al., 2011).
While HDT/ASCR and allo-SCT remain viable treatment
options for younger patients whose disease relapsed, a significant
response to systemic therapy must be achieved prior to using
these consolidation alternatives. Furthermore, appropriate treat-
ment for older or unfit patients is subject of much controversy as
high-dose therapy-based consolidation is not an option.
Suboptimal results of B-cell derived therapies led investigators
to design clinical trials specifically for PTCL. Given the rarity of
the disease and no established standard of care in the relapse set-
ting, most data comes from non-randomized phase II trials or case
series. Table 2 depicts current approaches for relapsed/refractory
disease.
CHEMOTHERAPY
In studies with heavily pretreated patients with a diagnosis of
PTCL, gemcitabine has shown activity as monotherapy, yielding
ORR of 60–70% (Zinzani et al., 1998; Sallah et al., 1999). A recent
report on the long-term follow-up of patients with relapsed PTCL
treated with gemcitabine as monotherapy confirmed the activity
of this agents, with a CR and PR rate in the PTCL-NOS popula-
tion of 30 and 25%, respectively (Zinzani et al., 2010). Five out of
20 patients with PTCL-NOS presented continuous CR at the time
of final follow-up, with a median duration of CR of 34 months
(range 15–60 months).
Clofarabine is a purine nucleoside analog that has been
reported as being active in the treatment of PTCL. A recent interim
report on a phase I/II study of clofarabine as monotherapy for
patients with relapsed/refractory PTCL has shown a ORR of 21%,
with mild and manageable side effects (Mulford et al., 2010).
Forodesine is a novel purine nucleoside analog, which inhibits
the enzyme purine nucleoside phosphorylase, responsible for
cleaving deoxyguanine to guanine. With deactivation of this
enzyme, deoxyguanine is instead converted to deoxyguano-
sine triphosphate (dGTP), leading intracellular accumulation of
this compound, causing apoptosis and reduced proliferation of
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Table 2 | Novel agents for treatment of PTCL (in the relapsed setting, unless otherwise specified).
Agent ORR (%) CR (%) OS/PFS/duration of response
(DOR)
CHEMOTHERAPY
Gemcitabine (Zinzani et al., 2010) 60–70 30 DOR 34 months
Clofarabine (Mulford et al., 2010) 21 0 N/A
Forodesine (Duvic et al., 2007) 39 0 DOR 127 days
Nelarabine (Czuczman et al., 2007) 10 0 DOR 1.2 months
Bendamustine (Damaj et al., 2013) 50 28 (after three cycles) DOR 3.5 months
IMMUNOTHERAPY
Denileukin diftitox (Dang et al., 2007) 48 22 PFS 6 months
Denileukin diftitox+CHOP (Foss et al., 2013)
(frontline)
65 N/A DOR 30 months
PFS 12 months
FOLATE ANALOGS
Pralatrexate (O’Connor et al., 2011) 29 11 PFS 3.5 months
OS 14.5 months
HISTONE DEACETYLASE INHIBITORS
Romidepsin (Coiffier et al., 2012) 25 15 CR/CRu DOR: 89% sustained CR at
13.4 months
Belinostat (Zain et al., 2010) 32 N/A DOR 8 months
ANTIBODIES
Brentuximab vedotin (for ALCL) (Pro et al.,
2012)
86 57 DOR 12.6 months
Zanolimumab (d’Amore et al., 2010) 21 N/A N/A
Alemtuzumab (low dose) (Zinzani et al., 2005) 50 33 N/A
Mogamulizumab (for ATL) (Ishida et al., 2012) 50 30.7 PFS 5.2 months
OS 13.7 months
PROTEASOME INHIBITORS
Bortezomib+CHOP (frontline) (Kim et al.,
2012)
67–76 62–65 3-year OS 47%
3-year PFS 35%
IMMUNOMODULATORY DRUGS
Lenalidomide (Dueck et al., 2010) 30 0 PFS 96 days
AURORA KINASE INHIBITORS
Alisertib (Friedberg et al., 2011) 57 N/A N/A
OTHER DEPSIPEPTIDES
Plitidepsin (Ribrag et al., 2013) 20.7 CR 6.8 N/A
PR 13.8
TKIs
Dasatinib (William et al., 2010) 32 (for all NHLs enrolled) CR: two patients with PTCL 2-year PFS 13% (for all patients)
PR: one patient with PTCL 2-year OS 50% (for all patients)
lymphocytes. This is a unique mechanism of action among
purine nucleoside analogs, which usually exert their antineoplastic
function through interaction with nucleic acids (Kicska et al.,
2001). Forodesine has been shown to selectively inhibit T-
lymphocytes, and was investigated as an agent for CTCL. In a phase
I/II study (Duvic et al., 2007), patients received oral forodesine
at escalated doses. Although a maximum tolerated dose (MTD)
was not reached, the optimal biological dose was determined as
being 80 mg/m2 daily. Thirty-six patients received the optimal
dose, yielding an ORR of 39% with a median duration of response
of 127 days. To date, there is no published data on forodesine used
for non-cutaneous PTCL.
Nelarabine, a pro-drug of arabinofuranosylguanine (ara-
G), is toxic to mature T-cells and immature T-lymphoblasts,
and has been approved by the FDA for use in the treat-
ment of relapsed or refractory T-ALL and T-lymphoblastic
lymphoma. This agent has been investigated in a phase II
trial, in adults with relapsed/refractory PTCL or systemically
untreated CTCL (Czuczman et al., 2007). Out of 19 patients,
only 2 presented partial remission, and median EFS was
1.2 months. Additionally, 33% of patients experienced Grade
3 or 4 neurologic toxicities, deeming this agent too toxic
and with low efficacy in the treatment of CTCL or PTCL as
monotherapy.
Recently, an open label, prospective phase II trial reported on
the use of bendamustine for patients with relapsed/refractory
PTCL (Damaj et al., 2013). Bendamustine is a “dual-structure”
drug, with an alkylating portion, derived from nitrogen mustard,
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and a purine analog portion. Bendamustine does not present
cross-resistance with other alkylating agents, and only presents
partial cross-resistance with other DNA binding agents. In this
trial, patients with relapsed PTCL or CTCL stage IIB or higher
(excluding Sezary syndrome) who received three or less lines
of systemic therapies, were enrolled, to receive bendamustine
120 mg/m2 per day over 30–60 min on days 1 and 2 every 3 weeks,
for a total of six cycles. Of the 60 enrolled patients, 15 received the
planned six cycles of bendamustine, 25 patients (42%) received
three to five cycles, and 20 patients (33%) received fewer than three
cycles. Early discontinuation occurred either due to progressive
disease (PD) (53%) or significant side effects from therapy. ORR
achieved after three cycles of bendamustine was 50%, including
CR/CRu of 28% and PR of 22%. Three patients had stable disease,
and 27 patients (45%) had PD. Four patients with PR after three
cycles converted their response to CR after six cycles. Median dura-
tion of response was 3.5 months, with 30% of responses lasting
more than 6 months. This study confirms the efficacy of ben-
damustine as a single agent for relapsed PTCL, and paves the way
for future studies incorporating bendamustine into multi-drug
regimens.
DENILEUKIN DIFTITOX
Denileukin diftitox, a genetically engineered drug combining the
full human sequence of IL-2 with the cytotoxic and membrane-
translocating domains of the diphtheria toxin, was tested in a
phase II study for patients with relapsed/refractory PTCL (n= 27),
yielding ORR of 48%, with a CR rate of 22% and a median PFS
of 6 months (Dang et al., 2007). When responses were evaluated
based on CD25 status, ORR was 61.5% for patients with CD25 pos-
itive tumors and 45.5% for patients with CD25 negative tumors.
Adverse events in this study were mild and transient.
The recently published phase II CONCEPT trial enrolled 49
patients with newly diagnosed PTCL. Patients received denileukin
diftitox with CHOP every 21 days, for six to eight cycles (Foss et al.,
2013). In the intent-to-treat population, ORR was 65%, with a
median duration of response of 30 months, and median PFS of
12 months. OS rate at the end of the study was 63.3% (median
OS not achieved). There were three treatment related deaths, and
most grade 3 or higher adverse events were hematologic.
FOLATE ANALOGS
Pralatrexate, a novel folate analog, is designed to be internalized
by the reduced folate carrier (RFC), an oncofetal protein that reg-
ulates internalization of natural folates required for biosynthesis
of DNA bases, and is expressed on both embryonic and malignant
tissues. Pralatrexate has a high affinity for RFC, which may lead
to selective tumor accumulation (Wang et al., 2003). Early phase
I/II trials of pralatrexate in patients with relapsed B- or T-cell lym-
phomas established its efficacy in this setting, yielding an ORR of
54% for patients with PTCL (O’Connor et al., 2009).
A large, pivotal phase II study (PROPEL study) established
the role for pralatrexate in relapsed/refractory PTCL (O’Connor
et al., 2011). One hundred and fifteen patients, across 25 different
centers, were enrolled in this study, with 111 patients receiving
pralatrexate. All patients had received at least one previous line
of therapy for PTCL. Treatment regimen consisted of pralatrexate
30 mg/m2 weekly for 6 out of 7 weeks, continuing until disease
progression or unacceptable toxicities. Overall response rate was
29%, including 11% CRs, with median PFS and OS of 3.5 and
14.5 months respectively. Although supplementation with folic
acid and vitamin B12 was provided, a significant rate of grade
3/4 mucositis (22%) and cytopenias occurred (32% thrombocy-
topenia, 22% neutropenia, and 18% anemia). Pralatrexate was the
first FDA-approved single agent for the treatment of patients with
relapsed/refractory PTCL.
HISTONE DEACETYLASE INHIBITORS
Increased histone acetylation has been shown to induce antitumor
activity through increased tumor suppressor gene transcription,
growth inhibition, cell cycle regulation, and apoptosis (Cress and
Seto, 2000; Santini et al., 2007). Romidepsin is a potent histone
deacetylase (HDAC) inhibitor, functioning at nanomolar concen-
trations, and shown to have activity in PTCL in phase I and II trials
(Piekarz et al., 2001, 2011). A large, international, pivotal phase II
study of romidepsin in relapsed/refractory PTCL was conducted,
enrolling 131 patients, with a primary endpoint of assessing the
rate of complete responses (Coiffier et al., 2012). ORR was reported
at 25%, with a 15% rate of CR/CRu (Complete response, uncon-
firmed) as assessed by an independent review committee. Of the
patients who achieved CR/CRu, 89% had a sustained response,
without evidence of progression of disease at a median follow-up
of 13.4 months. Grade 3/4 toxicities were mainly hematologic and
manageable with blood products or growth factor support. This
trial led to the FDA-approval of romidepsin as therapy for patients
with relapsed/refractory PTCL.
Based on the positive results achieved with romidepsin, addi-
tional HDAC inhibitors are being studied in PTCL. Belinostat, a
potent class I and II HDAC inhibitor, is being studied in a phase
II clinical trial (ClinicalTrials.gov Identifier: NCT00865969) for
patients with PTCL whose disease progressed after at least one line
of systemic therapy. At a dose of 1000 mg/m2 IV for days 1–5 of a
21-day cycle, the interim efficacy report for this trial has revealed
an ORR of 32% with a median duration of response of 8 months
(Zain et al., 2010). Panobinostat is a pan-HDAC inhibitor, tested
across a spectrum of hematological malignancies, with few PTCL
patients receiving this drug, although some responses have been
reported in this patient population (Ottmann et al., 2008). Vorino-
stat is a HDAC inhibitor approved for use in CTCL, without any
trials published, to date, of its use in PTCL.
ANTIBODY-DIRECTED THERAPY
The pilot study for alemtuzumab, a monoclonal antibody directed
to CD52 (a molecule highly expressed by malignant T-cells), in
relapsed/refractory PTCL used a rapidly escalating dosage sched-
ule during the first week of treatment, to achieve a maximum
dose of 30 mg intravenously three times per week for a maxi-
mum of 12 weeks (Enblad et al., 2004). Of the 14 patients enrolled
in the study, 5 (36%) showed some degree of response, with 3
(21%) CRs, although the treatment was deemed too toxic, with
cytomegalovirus reactivation in 6 patients, pulmonary aspergillo-
sis in 2 patients, Epstein–Barr virus-related hemophagocytosis in
2 patients, significant pancytopenia in 4 patients, and 5 patients
dying of causes related to treatment. A subsequent Phase II
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study of reduced-dose alemtuzumab (10 mg three times/week,
for 4 weeks) in patients with relapsed PTCL (n= 10; PTCL-
NOS, n= 6) showed a ORR of 50% (CR 33%) in the pop-
ulation subset of patients with PTCL-NOS, with significantly
less toxicities than the pilot study (Zinzani et al., 2005). This
has established alemtuzumab as a viable treatment option for
relapsed/refractory PTCL.
Zanolimumab is a fully human monoclonal antibody targeted
to the CD4 receptor, a molecule found in most T-lymphocytes.
This drug induces antibody-dependent cell cytotoxicity (ADCC),
direct apoptosis of CD3/CD4 positive cells and decreases T-cell
activation by interfering with CD4-MHC class II interaction.
A phase II multicenter study investigated zanolimumab in 21
patients with relapsed/refractory PTCL (d’Amore et al., 2010).
Based on previous data of CTCL (Kim et al., 2007b), the inves-
tigators used a dose of 980 mg weekly. ORR was reported at
21%, with two unconfirmed CRs. Patients tolerated zanolimumab
well, with most serious adverse events being related to infusion
reactions.
Siplizumab is a human monoclonal antibody targeted to CD2,
a molecule found in human T-lymphocytes and NK cells. A phase
I trial of this drug in T-cell lymphoproliferative disorders was ini-
tiated, and although initial reports (O’Mahony et al., 2005) found
siplizumab to be well tolerated and a MTD was not reached, follow-
up reports found an increased rate of Epstein–Barr virus-related
lymphoproliferative disorders (O’Mahony et al., 2009), probably
due to the profound T-cell depletion caused by siplizumab while
preserving B-cell numbers.
For the subset of PTCL patients diagnosed with systemic ALCL,
brentuximab vedotin (BV) has emerged as a very interesting ther-
apeutic approach. This antibody-drug conjugate (ADC) combines
a monoclonal antibody targeted to CD30 with a potent antimicro-
tubule agent (monomethyl auristatin E, MMAE). CD 30 represents
an ideal target in ALCL given the strong and uniform positivity.
After binding to its target molecule, BV is internalized and MMAE
is cleaved from the antibody molecule, exerting its action through
inhibition of microtubule formation. BV was evaluated in a mul-
ticenter phase II trial for patients with relapsed systemic ALCL, at
a dose of 1.8 mg/kg IV, every 3 weeks, for up to 16 cycles (Pro et al.,
2012). The ORR, as assessed by an independent review committee,
was reported at 86%, with a CR rate of 57%. The median durations
of overall response and CR were 12.6 and 13.2 months, respec-
tively. Significant grade 3/4 adverse events (≥10% of patients)
were neutropenia (21%), thrombocytopenia (14%), and periph-
eral sensory neuropathy (12%). BV was approved by the FDA for
treatment of systemic ALCL in patients who received at least one
prior multiagent chemotherapy regimen.
Adult T-cell leukemia/lymphoma is an aggressive peripheral
T-cell malignancy caused by the HTLV-I. This disease is more
prevalent in geographical areas where HTLV-I is endemic, such
as the Caribbean and Japan. Limited treatment options exist, and
this disease carries a very poor prognosis. Most tumor cells of
patients with ATL express CC chemokine receptor 4 (CCR4),
which may represent an ideal target for treatment of this dis-
ease. Mogamulizumab (KW-0761), a humanized anti-CCR4 IgG1
monoclonal antibody with a defucosylated Fc region has been
tested in this disease. The defucosylation of the Fc region results
in enhanced ADCC, which was demonstrated in vitro, prompting
a phase I trial in humans, which demonstrated good tolerability at
the recommended dose of 1.0 mg/kg (Yamamoto et al., 2010).
A multicenter phase II trial of mogamulizumab (Ishida et al.,
2012) for patients with a diagnosis of ATL whose disease had
relapsed after at least one prior chemotherapy regimen was per-
formed. Of 26 patients evaluable for efficacy, 13 achieved an
objective response (ORR 50%), with eight CRs. Median PFS and
OS were 5.2 and 13.7 months, respectively. The most common
AE was an infusion reaction in 89% of patients, which was man-
ageable with symptomatic medication. Mogamulizumab has been
approved in Japan for the treatment of relapsed/refractory ATL
and phase II studies are underway for PTCLs in Europe and
the US.
IMMUNOMODULATORY DRUGS
Lenalidomide has been evaluated as monotherapy for patients
with relapsed/refractory PTCL in a phase II trial (Dueck et al.,
2010). Twenty-four patients were enrolled and received lenalido-
mide at 25 mg daily, for 21 out of 28 days. The interim analysis of
this study reported ORR of 30%, without any CRs achieved and a
median PFS of 96 days. Lenalidomide is an oral agent, with a broad
range for dose adjustments, and should be evaluated in conjunc-
tion with standard chemotherapy or other biological agents, such
as bortezomib.
AURORA KINASE INHIBITORS
Aurora kinases are a family of oncogenic protein kinases that
have a regulatory role in the cell mitotic process. Up-regulation of
Aurora A kinase (AAK) has been reported in non-cutaneous PTCL,
and has been correlated with rapidly dividing histologic subtypes
(Mahadevan et al., 2005; Ikezoe et al., 2009; Kanagal-Shamanna
et al., 2013). Alisertib (MLN8237) is a selective inhibitor of AAK,
and has shown pre-clinical activity in PTCL cell lines and patient
samples (Qi et al., 2013). Recently, interim results of a phase II
clinical trial of alisertib in patients with aggressive B and T-cell
NHL were reported (Friedberg et al., 2011). In this trial, patients
were treated with alisertib at a dose of 50 mg twice daily for 7 days
on 21-day cycles, until PD or unacceptable toxicities. Of the 48
enrolled patients, 17% had a diagnosis of PTCL. ORR for the whole
study population was 32%, but when divided by subtype, patients
with a diagnosis of PTCL presented an ORR of 57%. Currently, a
phase III study of alisertib versus investigator’s choice of treatment
is underway for patients with relapsed PTCL (ClinicalTrials.gov:
#NCT01482962).
PLITIDEPSIN
Plitidepsin is a cyclic depsipeptide which has shown activity
against multiple cancer cell lines, including leukemias and lym-
phomas. A recent, multicenter phase II trial evaluated the use
of plitidepsin as a single agent for the treatment of patients
with relapsed/refractory NHLs (Ribrag et al., 2013). Patients were
divided into two large cohorts, including one for non-cutaneous
PTCL (n= 34). Plitidepsin was administered as an 1 h intra-
venous infusion, at 3.2 mg/m2, on days 1, 8, and 15, every 4 weeks.
Among the 29 evaluable patients with non-cutaneous PTCL, six
had a response (two CRs, four PRs, ORR 20.7%). Most adverse
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events were mild and transient, and easily managed by dose
adjustments.
TYROSINE KINASE INHIBITORS
Several groups have described aberrant tyrosine kinase signaling
in PTCL cell lines (Piccaluga et al., 2005, 2007; Huang et al., 2010;
Piva et al., 2010). Particularly, PTCL-NOS has been found to over-
express constitutively phosphorylated platelet derived growth fac-
tor receptor alpha (PDFGRA). These findings have led to trials
of Tyrosine kinase inhibitors (TKIs) in PTCL, since PDGFRA is
one of multiple targets of this class of drugs. Initial findings of
a phase I/II trial of dasatinib in relapsed/refractory NHL were
reported (William et al., 2010). This study enrolled 27 patients
with NHL, with relapsed or refractory disease after at least one
prior systemic therapy. For the 19 evaluable patients, the ORR was
32%, with a median 2-year PFS and OS of 13 and 50% respec-
tively. The only two patients who presented a CR had a diagnosis
of PTCL, and remained alive and disease free for at least 2 years
after treatment. An additional patient with PTCL achieved a partial
response.
DISCUSSION
Peripheral T-cell lymphomas comprise a heterogeneous group of
NHLs, with different clinical and biological behaviors, but with
a common denominator of poor overall prognosis and lack of
potentially curable approaches outside of the realm of stem-cell
transplantation. Excluding ALK+ anaplastic large cell lymphoma,
which is associated with a good prognosis (5-year OS 70%), and
ALK-negative anaplastic large cell lymphoma (5-year OS 49%),
the overall 5-year survival for other common subtypes of periph-
eral T-cell lymphomas is about 30–35%. However, in the last
few years there have been an increasing number of trials in
PTCL, and a number of novel agents are now approved in the
relapsed/refractory setting, which hopefully will change the sur-
vival rates over the next few years, once these agents are more
widely used by the medical community. Also, new insights into
the molecular pathogenesis of PTCL, may lead to studies focusing
on newer targeted agents.
Future endeavors for the treatment of PTCL should focus on
developing trials specific for different subtypes, and exploring
novel combination therapies in the frontline setting.
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